Described herein are compositions comprising a prostaglandin FP receptor agonist (PFPRA) compound and a fatty acid, e.g., oleic acid, that, when topically applied to the skin, locally delivers a therapeutically effective amount of the PFPRA compound or active metabolite thereof to subcutaneous fat under the skin. The therapeutic effect is, for example, reduction of the subcutaneous fat under the skin. Further provided are methods of reducing body fat in a subject comprising topically administering the composition to the subject. The present invention also provides kits comprising the composition and instructions for use.

Described herein are compositions comprising a prostaglandin FP receptor agonist (PFPRA) compound and a fatty acid, e.g., oleic acid, that, when topically applied to the skin, locally delivers a therapeutically effective amount of the PFPRA compound or active metabolite thereof to subcutaneous fat under the skin. The therapeutic effect is, for example, reduction of the subcutaneous fat under the skin. Further provided are methods of reducing body fat in a subject comprising topically administering the composition to the subject. The present invention also provides kits comprising the composition and instructions for use.

A method is provided for diminishing wrinkles, fine lines, blemishes, skin discoloration, cellulite, and/or bruising in human skin including administering a topical treatment on a patient's skin. The topical treatment includes Hyaluronic Acid; a suspension mixture; Tetrahydropiperine, Horse Chestnut Extract, Lecithin; and an effective dose of at least 0.5% of a compound indole-3-carbinol or its derivatives. The topical treatment is applied to the patient's skin in need of diminishment in wrinkles, fine lines, blemishes, skin discoloration, cellulite, and/or bruising.

Disclosed is a method of treating a fine line or wrinkle in a person's skin, the method comprising topically applying to the fine line or wrinkle a composition comprising an effective amount of Commiphora mukul resin or an extract thereof that includes oleo gum resin, glycerin, water, and hyaluronic acid or a salt form thereof, wherein topical application of the composition to the fine line or wrinkle reduces the appearance of the fine line or wrinkle.

The invention relates to stable liquid neurotoxin formulations which are free of animal proteins, comprising a surfactant, an amino acid selected from tryptophan and tyrosine, a buffer comprising sodium, chloride and phosphate ions, which have a pH between 5.5 and 8, and which are stable for 2 months. These compositions are suitable for use in therapy and in particular for administration to a patient to achieve a desired therapeutic or aesthetic effect. The invention also relates to the use of an amino acid selected from tryptophan and tyrosine to protect a proteinaceous neurotoxin from degradation in a liquid composition which is free of animal derived proteins.

The present disclosure provides a mixture of sugar apple and rosemary extracts, optionally in combination with prickly ash extract, for use as skin care compositions.

The present disclosure provides a mixture of sugar apple and rosemary extracts, optionally in combination with prickly ash extract, for use as skin care compositions.

The present disclosure relates to a method for rating the severity of cellulite on a thigh or buttock in a human subject by utilizing a photonumeric scale that provides reliable results from physician-to-physician and patient-to-patient.

The present disclosure relates to a method for rating the severity of cellulite on a thigh or buttock in a human subject by utilizing a photonumeric scale that provides reliable results from physician-to-physician and patient-to-patient.

A method for the expression and/or for the amplification of the expression of thrombospondin-1, fibronectin, vimentin and/or mimecan in human skin. The method comprises applying to human skin at least one caviar extract which is capable of causing the expression and/or the amplification of the expression of thrombospondin-1, fibronectin, vimentin and/or mimecan in human skin.